CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 130 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2020. The put-call ratio across all filers is 0.95 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,122,513 | -35.0% | 40,789 | -19.8% | 0.00% | -50.0% |
| Q2 2023 | $1,726,019 | +32.3% | 50,870 | +40.3% | 0.00% | +100.0% |
| Q1 2023 | $1,304,419 | -13.5% | 36,254 | +7.2% | 0.00% | -50.0% |
| Q4 2022 | $1,507,134 | +57.0% | 33,815 | -1.0% | 0.00% | +100.0% |
| Q3 2022 | $960,000 | +19.1% | 34,156 | +14.2% | 0.00% | 0.0% |
| Q2 2022 | $806,000 | -18.3% | 29,907 | +3.4% | 0.00% | 0.0% |
| Q1 2022 | $986,000 | -9.2% | 28,932 | +2.9% | 0.00% | 0.0% |
| Q4 2021 | $1,086,000 | -33.3% | 28,105 | -6.8% | 0.00% | 0.0% |
| Q3 2021 | $1,629,000 | +84.5% | 30,164 | +14.2% | 0.00% | – |
| Q2 2021 | $883,000 | -12.4% | 26,422 | -46.0% | 0.00% | -100.0% |
| Q1 2021 | $1,008,000 | -15.2% | 48,954 | -27.8% | 0.00% | 0.0% |
| Q4 2020 | $1,189,000 | +1950.0% | 67,792 | +92.0% | 0.00% | – |
| Q1 2020 | $58,000 | – | 35,317 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |